{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:03:48Z","timestamp":1789643028876,"version":"4.0.0"},"reference-count":127,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Diabetes mellitus and obesity represent a growing global health burden with high morbidity and mortality. In the last several years, novel incretin-based therapies have been developed, and their use has risen dramatically. Beyond their proven metabolic, glycemic, cardiovascular, renal, and many other benefits, there are some observational data linking anemia development with their use. From the era of gliptins to retatrutide, in this review we tried to explore whether erythroid suppression is the hidden paradigm of advanced incretin-based therapies. Potential pathophysiological explanations include micronutrient vulnerabilities due to reduced food intake, lower dietary diversity, gastrointestinal intolerance, delayed gastric emptying, and weight loss. The most important concerns involve deficiencies in iron, vitamin B12, vitamin B2, vitamin D, calcium, magnesium, and zinc, along with others such as thiamine, folate, vitamin A, and potassium. The available evidence indicates a complex and heterogeneous relationship between incretin-based therapies and hematological parameters, with findings differing across therapies, study populations, and outcomes. Although observational studies suggest possible associations with anemia, iron deficiency, and nutritional deficiencies in selected populations, current evidence is insufficient to establish a direct causal relationship or a class-wide adverse effect. Further large-scale studies are needed, as well as increased clinician awareness of potential hematological and nutritional consequences that require laboratory follow-up before and during medication prescription.<\/jats:p>","DOI":"10.3390\/medsci14050577","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:59:03Z","timestamp":1789639143000},"page":"577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?"],"prefix":"10.3390","volume":"14","author":[{"given":"Maja","family":"Mizdrak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Split, Split School of Medicine, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Batisti\u0107","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Split, Split School of Medicine, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Mizdrak","sequence":"additional","affiliation":[{"name":"Department of ENT, University Hospital of Split, Split School of Medicine, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kawanami, D., Matoba, K., Sango, K., and Utsunomiya, K. (2016). Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17081223"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lee, A.A., Khotina, V.A., Kashirskikh, D.A., Voronko, O.E., Gasanov, V.A., and Vasiliev, A.V. (2025). Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact. Med. Sci., 13.","DOI":"10.3390\/medsci13040269"},{"key":"ref_3","first-page":"280","article-title":"Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites","volume":"55","author":"Chen","year":"2025","journal-title":"J. Orthop. Transl."},{"key":"ref_4","unstructured":"Magliano, D.J., and Boyko, E.J. (2026, July 23). Diabetes Atlas 11th Edition Scientific Committee, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK618744\/."},{"key":"ref_5","unstructured":"Global Market Insights (2026, September 05). The Glucagon-Like Peptide-1 (GLP-1) Agonists Market Report (Report ID: MGR105407; SKU ID: 21605384); Global Market Insights. Available online: https:\/\/www.gminsights.com."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-World Evidence on the Utilization, Clinical and Comparative Effectiveness, and Adverse Effects of Newer GLP-1RA-Based Weight-Loss Therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_8","unstructured":"European Medicines Agency (2026). Ozempic (Semaglutide): EPAR\u2014Product Information, European Medicines Agency."},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2026). Ozempic (Semaglutide) Injection, for Subcutaneous Use: Prescribing Information, U.S. Food and Drug Administration."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the Two Incretin Hormones: Similarities and Differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2016.10.007","article-title":"Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis","volume":"25","author":"Mulvihill","year":"2017","journal-title":"Cell Metab."},{"key":"ref_12","first-page":"538","article-title":"Effects of dipeptidyl peptidase-4 on the hematopoiesis and transplantation","volume":"36","author":"Li","year":"2014","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/nm.2991","article-title":"Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis","volume":"18","author":"Broxmeyer","year":"2012","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1089\/neu.2015.4229","article-title":"Glucose-Dependent Insulinotropic Polypeptide ameliorates mild traumatic brain injury-induced cognitive and sensorimotor deficits and neuroinflammation in rats","volume":"33","author":"Yu","year":"2016","journal-title":"J. Neurotrauma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"171200","DOI":"10.1016\/j.peptides.2024.171200","article-title":"Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut","volume":"176","author":"Morrow","year":"2024","journal-title":"Peptides"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2013.04.007","article-title":"Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond","volume":"229","author":"Fadini","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1097071","article-title":"Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26\/Dipeptidylpeptidase IV","volume":"305","author":"Christopherson","year":"2004","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103008","DOI":"10.1016\/j.stemcr.2026.103008","article-title":"GLP-1 Regulates Osteo-Adipogenic Fate of BMSCs via HIF-2-AKT Signaling and Supports Trabecular Bone in Glucocorticoid-Induced Osteoporosis","volume":"21","author":"Yang","year":"2026","journal-title":"Stem Cell Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","article-title":"Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-catenin","volume":"6","author":"Meng","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Shen, Y., Zhang, M., Yang, T., Wu, Y., Qiu, Y., Zhang, L., Li, F., Chen, M., Chen, Q., and Wei, W. (2026). The promoting roles of GLP1R and GIPR in stemness maintenance and multiple lineage-specific differentiation of PDLSCs. Cell. Mol. Biol. Lett., 31.","DOI":"10.1186\/s11658-026-00867-2"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"115553","DOI":"10.1016\/j.bone.2020.115553","article-title":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis","volume":"140","author":"Helsted","year":"2020","journal-title":"Bone"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.4049\/jimmunol.1601441","article-title":"Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis","volume":"198","author":"Mantelmacher","year":"2017","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e34538","DOI":"10.1097\/MD.0000000000034538","article-title":"The effect of Dipeptidyl peptidase 4 (DPP-4) inhibitors on hemoglobin level in diabetic kidney disease: A retrospective cohort study","volume":"102","author":"Zeng","year":"2023","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/ijc.20091","article-title":"Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells","volume":"109","author":"Wesley","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/onc.2008.402","article-title":"Suppression of neuroblastoma growth by dipeptidyl peptidase IV: Relevance of chemokine regulation and caspase activation","volume":"28","author":"Arscott","year":"2009","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.190.3.311","article-title":"A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells","volume":"190","author":"Wesley","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","article-title":"Skin homing of S\u00e9zary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV","volume":"107","author":"Narducci","year":"2006","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Busek, P., Duke-Cohan, J.S., and Sedo, A. (2022). Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?. Cancers, 14.","DOI":"10.3390\/cancers14092072"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000515704","article-title":"Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus","volume":"46","author":"Hasegawa","year":"2021","journal-title":"Kidney Blood Press. Res."},{"key":"ref_30","first-page":"4614","article-title":"Do DPP-4 enzyme inhibitors affect hemoglobin, leucocyte and thrombocyte levels in patients with type 2 diabetes mellitus?","volume":"27","author":"Merdin","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1111\/dom.70057","article-title":"SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany","volume":"27","author":"Sarabhai","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s11606-024-08640-x","article-title":"Association Between SGLT2 Inhibitor Use and Change in Hemoglobin Among Adults with Diabetes: A Nationwide Cohort Study","volume":"39","author":"Lassen","year":"2024","journal-title":"J. Gen. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2027372","article-title":"Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease","volume":"384","author":"Farag","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gutjnl-2015-310572","article-title":"GLP-1 based therapies: Clinical implications for gastroenterologists","volume":"65","author":"Smits","year":"2016","journal-title":"Gut"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The Cardiovascular Biology of Glucagon-like Peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07435800.2014.966385","article-title":"Short-Term Intervention with Liraglutide Improved Eating Behavior in Obese Women with Polycystic Ovary Syndrome","volume":"40","author":"Jensterle","year":"2015","journal-title":"Endocr. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process","volume":"407","author":"Teede","year":"2026","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e174825","DOI":"10.1172\/jci.insight.174825","article-title":"Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice","volume":"10","author":"Hammoud","year":"2024","journal-title":"JCI Insight"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ndt\/gfaf193","article-title":"The Effect of GLP-1 Receptor Agonists on Renal Outcomes: A Systematic Review and Meta-Analysis","volume":"41","author":"Sasaki","year":"2026","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41581-025-01036-y","article-title":"GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease","volume":"22","author":"Alicic","year":"2026","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103468","DOI":"10.1016\/j.redox.2024.103468","article-title":"Liraglutide and GLP-1(9\u201337) alleviated hepatic ischemia-reperfusion injury by inhibiting ferroptosis via GSK3\u03b2\/Nrf2 pathway and SMAD159\/Hepcidin\/FTH pathway","volume":"79","author":"Lu","year":"2025","journal-title":"Redox Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","article-title":"Hepcidin and Iron Homeostasis","volume":"1823","author":"Ganz","year":"2012","journal-title":"Biochim. Biophys. Acta BBA Mol. Cell Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-med-043021-032816","article-title":"Hepcidin and Iron in Health and Disease","volume":"74","author":"Nemeth","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102777","DOI":"10.1016\/j.bcmd.2023.102777","article-title":"Hypoferremia of inflammation: Innate host defense against infections","volume":"104","author":"Ganz","year":"2024","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_51","first-page":"e243780","article-title":"Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual Agonist Versus Monoagonist Treatment in a Mouse Model","volume":"312","author":"Sun","year":"2024","journal-title":"Radiology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100186","DOI":"10.1016\/j.obpill.2025.100186","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study","volume":"15","author":"Butsch","year":"2025","journal-title":"Obes. Pillars"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ncp.11228","article-title":"Malnutrition in patients with obesity: An overview perspective","volume":"39","author":"Cristancho","year":"2024","journal-title":"Nutr. Clin. Pract."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e70070","DOI":"10.1111\/cob.70070","article-title":"Micronutrient and Nutritional Deficiencies Associated with GLP-1 Receptor Agonist Therapy: A Narrative Review","volume":"16","author":"Urbina","year":"2026","journal-title":"Clin. Obes."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"907","DOI":"10.15537\/smj.2025.46.8.20240100","article-title":"GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study","volume":"46","author":"Almuammar","year":"2025","journal-title":"Saudi Med. J."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lama, S., Chaudhuri, S., Blankenship, D., Ban, A.N., Usvyat, L., Pecoits-Filho, R., and Hippen, B.E. (2026). Real-World Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients on Hemodialysis. Kidney Med., 101476.","DOI":"10.1016\/j.xkme.2026.101476"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Infante, M., Ricordi, C., Pacifici, F., Pastore, D., Infante, R., Caprio, M., Chiereghin, F., De Stefano, A., Frank, G., and De Rose, A. (2026). Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency. Nutrients, 18.","DOI":"10.3390\/nu18132038"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1\u2013Renal Axis in Man","volume":"104","author":"Asmar","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/PRS.0000000000012672","article-title":"Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy","volume":"158","author":"Mehta","year":"2025","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.obpill.2026.100290","article-title":"Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework","volume":"19","author":"Rossetti","year":"2026","journal-title":"Obes. Pillars"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., and Jones, R. (2025). Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: A cross-sectional study. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1566498"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3945\/ajcn.114.097394","article-title":"Is achlorhydria a cause of iron deficiency anemia?","volume":"102","author":"Betesh","year":"2015","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0016-5085(81)80013-3","article-title":"Role of gastric acid in food iron absorption","volume":"81","author":"Skikne","year":"1981","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1590-8658(03)00067-7","article-title":"The stomach and iron deficiency anaemia: A forgotten link","volume":"35","author":"Annibale","year":"2003","journal-title":"Dig. Liver Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"G397","DOI":"10.1152\/ajpgi.00348.2013","article-title":"Mechanistic and regulatory aspects of intestinal iron absorption","volume":"307","author":"Gulec","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1017\/S0029665124007468","article-title":"Anaemia during pregnancy: Could riboflavin deficiency be implicated?","volume":"85","author":"Duffy","year":"2026","journal-title":"Proc. Nutr. Soc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1079\/BJN19880047","article-title":"The effect of riboflavin deficiency in rats on the absorption and distribution of iron","volume":"59","author":"Powers","year":"1988","journal-title":"Br. J. Nutr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1079\/BJN19860097","article-title":"The influence of riboflavin deficiency on absorption and liver storage of iron in the growing rat","volume":"56","author":"Adelekan","year":"1986","journal-title":"Br. J. Nutr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/nutrit\/nuac043","article-title":"Riboflavin intake and status and relationship to anemia","volume":"81","author":"Aljaadi","year":"2022","journal-title":"Nutr. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"149882","DOI":"10.1016\/j.bbrc.2024.149882","article-title":"Semaglutide alters gut microbiota and improves NAFLD in db\/db mice","volume":"710","author":"Mao","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e0203223","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng","year":"2024","journal-title":"mBio"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Dinkov, B., and Pendicheva-Duhlenska, D. (2026). The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD\/MASH in Type 2 Diabetes Mellitus: A Narrative Review. Biomedicines, 14.","DOI":"10.3390\/biomedicines14040806"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1111\/dom.16368","article-title":"The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus\u2014A pilot study","volume":"27","author":"Melis","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e240946","DOI":"10.1001\/jamanetworkopen.2024.0946","article-title":"Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients with Diabetes and CKD","volume":"7","author":"Hu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113341","DOI":"10.1016\/j.diabres.2026.113341","article-title":"Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study","volume":"237","author":"Lund","year":"2026","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e003300","DOI":"10.1136\/bmjdrc-2022-003300","article-title":"Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: A nationwide register-based study","volume":"11","author":"Bain","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"luaf104","DOI":"10.1210\/jcemcr\/luaf104","article-title":"Cystic fibrosis and hemochromatosis carriers may be prone to glucagon-like peptide-1 agonist pancreatitis: 3 cases","volume":"3","author":"Sydney","year":"2025","journal-title":"JCEM Case Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Nguefang, G.L., Boateng, S., Gyabaah, S., Issaka, Y., Konlack, J.G., Landa, E.L., Eze, E., and Njei, B. (2026). Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: A real-world cohort analysis. Orphanet J. Rare Dis., 21.","DOI":"10.1186\/s13023-026-04322-5"},{"key":"ref_80","unstructured":"GBD 2023 Disease and Injury and Risk Factor Collaborators (2025). Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023. Lancet, 406, 1873\u20131922."},{"key":"ref_81","first-page":"e101437","article-title":"Ischemic Colitis Associated with Tirzepatide Therapy in a Young Female Patient: A Case Report","volume":"18","author":"Sekhon","year":"2026","journal-title":"Cureus"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e01679","DOI":"10.14309\/crj.0000000000001679","article-title":"From Glycemic Control to Gut Telescoping: Intussusception in a Patient on a Glucagon-Like Peptide-1 Receptor Agonist","volume":"12","author":"Thakkar","year":"2025","journal-title":"ACG Case Rep. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.brci.2026.100089","article-title":"Association of glucagon-like peptide 1 receptor agonist use with erythropoietic indices and anemia risk in diabetes","volume":"1","author":"Woo","year":"2026","journal-title":"Blood Red Cells Iron"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e2076","DOI":"10.1210\/clinem\/dgag218","article-title":"Anti-inflammatory effects of GLP1-RA drugs","volume":"111","author":"Quintana","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Nauck, M.A., and D\u2018aLessio, D.A. (2022). Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc. Diabetol., 21.","DOI":"10.1186\/s12933-022-01604-7"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_91","first-page":"dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e047018","DOI":"10.1161\/JAHA.125.047018","article-title":"Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","volume":"15","author":"Wu","year":"2026","journal-title":"J. Am. Heart Assoc."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100248","DOI":"10.1016\/j.obpill.2026.100248","article-title":"Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials","volume":"17","author":"Almandoz","year":"2026","journal-title":"Obes. Pillars"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., and Tsioufis, K. (2025). Retatrutide\u2014A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15.","DOI":"10.3390\/biom15060796"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"156057","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S2213-8587(26)00100-2","article-title":"Beyond weight loss: Multisystem benefits of obesity medications","volume":"14","author":"Savas","year":"2026","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/dom.70209","article-title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","volume":"28","author":"Giblin","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/13543784.2023.2283020","article-title":"Retatrutide showing promise in obesity (and type 2 diabetes)","volume":"32","author":"Doggrell","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40292-026-00814-4","article-title":"Exploratory cardiovascular risk modeling of orforglipron using the PREVENT equations compared with the pooled cohort equations: A post-hoc analysis from a systematic review and meta-analysis","volume":"33","author":"Alper","year":"2026","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Nauck, M.A., and Quast, D.R. (2021). Cardiovascular Safety and Benefits of Semaglutide in Patients with Type 2 Diabetes: Findings from SUSTAIN 6 and PIONEER 6. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.645566"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_106","first-page":"105549","article-title":"Anemia risk and mitigation strategies in type 2 diabetic patients: The role of novel antidiabetic agents","volume":"16","year":"2025","journal-title":"World J. Diabetes"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1479164114542802","article-title":"The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system","volume":"11","author":"Schernthaner","year":"2014","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Rosseel, Z., Overwater, N.M.P., Aerts, M., Chapple, L.-a.S., Chen, D., Haines, K.L., Liu, J., Kouw, I.W.K., Ke, L., and Pichard, C. (2025). Towards Optimised Nutrition Therapy After Critical Illness: A Position Statement and Research Framework by the Global Research Initiative on Post-Intensive Care Nutrition (GRIP) Consortium. Crit. Care, 29.","DOI":"10.1186\/s13054-025-05710-2"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e2526321","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients with Type 2 Diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am. J. Manag. Care"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e2612133","DOI":"10.1001\/jamanetworkopen.2026.12133","article-title":"Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer","volume":"9","author":"Tatum","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s11606-025-09380-2","article-title":"Prescription Patterns for GLP-1 Receptor Agonists and SGLT2 Inhibitors by Physicians\u2019 Years in Practice","volume":"40","author":"Inoue","year":"2025","journal-title":"J. Gen. Intern. Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Tuccinardi, D., Zilich, R., Ponzani, P., Musacchio, N., Manicardi, V., Rocca, A., Pontremoli, R., Fioretto, P., Muscar\u00e0, A., and Di Cianni, G. (2025). Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: A machine learning-based large cohort analysis. Cardiovasc. Diabetol. Endocrinol. Rep., 11.","DOI":"10.1186\/s40842-025-00251-7"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cmi.2026.01.014","article-title":"The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: Network meta-analysis","volume":"32","author":"Zeng","year":"2026","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kazi, M.A.I., Singh, S., and Haq, N. (2025). Guts, Glucose, and Gallbladders: The Protective Role of GLP-1\/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14248882"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Shirmard, F.O., Pourfaraji, S.M., Omouri-Kharashtomi, M., and Amani, A. (2025). Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04496-5"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/oby.70221","article-title":"Prepregnancy GLP-1RA Exposure and Risk of Hypertensive Disorders of Pregnancy Among Women with Obesity and Diabetes","volume":"34","author":"Lemas","year":"2026","journal-title":"Obesity"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jamainternmed.2025.1794","article-title":"Integrating Diet and Physical Activity When Prescribing GLP-1s\u2014Lifestyle Factors Remain Crucial","volume":"185","author":"Mehrtash","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/oby.24336","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"33","author":"Mozaffarian","year":"2025","journal-title":"Obesity"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.cmet.2026.05.015","article-title":"Methionine-supplemented longevity diet increases growth hormone, GLP-1, and FGF21; reduces frailty; and promotes healthspan","volume":"38","author":"Fanti","year":"2026","journal-title":"Cell Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13679-025-00667-3","article-title":"A Multidisciplinary Perspective on Semaglutide Treatment and Medical Nutrition Therapy in Obesity Management","volume":"14","author":"Barrea","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Patern\u00f2, V., Geraci, G., Piticchio, T., Le Moli, R., Burgio, S., Costanzo, G., Sambataro, G., Baratta, R., Barbagallo, F., and Pallotti, F. (2026). Mediterranean diet adherence and tirzepatide: Real-world evidence on adiposity indices and insulin resistance beyond weight loss. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1700894"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Gorrita, C., Onofre, N.S., Merino-Torres, J.F., and Soriano, J.M. (2025). Beyond GLP-1 Agonists: An Adaptive Ketogenic\u2013Mediterranean Protocol to Counter Metabolic Adaptation in Obesity Management. Nutrients, 17.","DOI":"10.3390\/nu17162699"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.pcd.2024.06.002","article-title":"Knowledge and prescribing behaviour of Flemish general practitioners regarding novel glucose-lowering medications: Online cross-sectional survey","volume":"18","author":"Lecomte","year":"2024","journal-title":"Prim. Care Diabetes"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C.G., Porcellati, F., and Pippi, R. (2026). Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review. Nutrients, 18.","DOI":"10.3390\/nu18010131"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"c2181","DOI":"10.1136\/bmj.c2181","article-title":"Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial","volume":"340","author":"Kooy","year":"2010","journal-title":"BMJ"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:35:38Z","timestamp":1789641338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":127,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medsci14050577"],"URL":"https:\/\/doi.org\/10.3390\/medsci14050577","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}